

Coordinated Fc-effector and neutralization functions in HIV-infected children define a window of opportunity for HIV vaccination

Eunice W. Nduati^a, Mathew J. Gorman^b, Yiakon Sein^a,
Tandile Hermanus^c, Dansu Yuan^b, Ian Oyaro^a, Daniel M. Muema^{d,e},
Thumbi Ndung'u^{b,d,e,f,g}, Galit Alter^b and Penny L. Moore^{c,h}

Objectives: Antibody function has been extensively studied in HIV-infected adults but is relatively understudied in children. Emerging data suggests enhanced development of broadly neutralizing antibodies (bNAbs) in children but Fc effector functions in this group are less well defined. Here, we profiled overall antibody function in HIV-infected children.

Design: Plasma samples from a cross-sectional study of 50 antiretroviral therapy-naive children (aged 1–11 years) vertically infected with HIV-1 clade A were screened for HIV-specific binding antibody levels and neutralizing and Fc-mediated functions.

Methods: Neutralization breadth was determined against a globally representative panel of 12 viruses. HIV-specific antibody levels were determined using a multiplex assay. Fc-mediated antibody functions measured were antibody-dependent: cellular phagocytosis (ADCP); neutrophil phagocytosis (ADNP); complement deposition (ADCD) and natural killer function (ADNK).

Results: All children had HIV gp120-specific antibodies, largely of the IgG₁ subtype. Fifty-four percent of the children exhibited more than 50% neutralization breadth, with older children showing significantly broader neutralization activity. Apart from ADCC, observed only in 16% children, other Fc-mediated functions were common (>58% children). Neutralization breadth correlated with Fc-mediated functions suggesting shared determinants of enhanced antibody function exist.

Conclusions: These results are consistent with previous observations that children may develop high levels of neutralization breadth. Furthermore, the striking association between neutralization breadth and Fc effector function suggests that HIV vaccination in children could yield multifunctional antibodies. Paediatric populations may therefore provide an ideal window of opportunity for HIV vaccination strategies.

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc.

AIDS 2021, **35**:1895–1905

Keywords: antibodies, children, Fc-mediated function, HIV, neutralizing function, vaccines

^aKEMRI Wellcome Trust Research Programme, Kilifi, Kenya, ^bRagon Institute of MGH, MIT and Harvard, Cambridge, MA, USA, ^cNational Institute for Communicable Diseases of the National Health Laboratory Services, Johannesburg, ^dAfrica Health Research Institute, Durban, ^eHIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa, ^fMax Planck Institute for Infection Biology, Berlin, Germany, ^gDivision of Infection and Immunity, University College London, London, UK, and ^hAntibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

Correspondence to Eunice W. Nduati, KEMRI Wellcome Trust Research Programme, Kilifi, Kenya.

E-mail: Enduati@kemri-wellcome.org

Received: 19 January 2021; revised: 4 May 2021; accepted: 2 June 2021.

DOI:10.1097/QAD.0000000000002976

ISSN 0269-9370 Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Broadly neutralizing antibodies (bNAbs) to HIV-1 are of particular interest for vaccine-mediated humoral immunity. Studies in macaque models [1–4], humanized mice [5] and humans [6] have provided proof-of-principle that a vaccine capable of inducing these types of antibodies is likely to be effective against most circulating HIV strains. However, only a small proportion of HIV-infected individuals generate bNAbs [7] and no HIV vaccine candidate has been able to elicit antibodies with sufficient breadth [8,9].

Antibody functions have largely been described in adults but less is known for children despite their distinct course of HIV infection. AIDS typically develops more rapidly in paediatric HIV cases compared with adults [10–12] and infants and children rapidly develop broader and more potent neutralizing antibodies than adults [13–15]. Furthermore, an isolated bNAb from an infant showed low somatic hypermutation and lacked insertions and deletions typical of bNAbs from adults, suggesting that infants may have a more direct pathway to breadth that does not require years of affinity maturation [13].

Antibodies are, however, multifunctional and their antiviral activity results from the synergistic functions of the fragment antigen binding (Fab) and fragment crystallizable (Fc) regions [16,17]. Antibodies capable of mediating Fc-effector functions via innate immune cells are commonly identified in HIV-infected people, and may contribute to viral control [18,19] and to slowing HIV acquisition [20]. Additionally, elite controllers may have more Fc-mediated antibody polyfunctionality that recruits a more coordinated innate immune response [21]. In the only HIV vaccine trial that has shown any protection to date, lower risk of HIV acquisition was associated with Fc-mediated antibody functions [22]. Fc-mediated functions also contribute to optimal antiviral activity for some bNAbs [23]. bNAbs were shown to interfere with the establishment of a silent reservoir through Fc-Fc receptor-mediated mechanisms [24]. Furthermore, reduced protection by passively administered bNAbs occurred when Fc-receptor activity was engineered out of these antibodies [25]. In infected adults, HIV-specific Fc-effector functions early in HIV infection predicted the downstream development of bNAbs [26] but such studies have not been performed in children.

Understanding the development of broadly neutralizing and Fc-mediated antibody functions in paediatric natural HIV infection remains important. To address this, we assessed the presence, magnitude and correlation of neutralizing and Fc-mediated functions in a cross-sectional study of 50 antiretroviral therapy (ART)-naive, chronically infected children aged 1–11 years, predominantly infected with HIV clade A. Fifty-four percent of the children developed neutralization breadth against the

panel of viruses used in this study. There was a significant association of antibody neutralization breadth with the Fc-mediated functions suggesting common determinants of function. These results agree with the accumulating findings that children may have unique immunological profiles that favour the development of more effective antibodies and understanding of these profiles may inform vaccine strategy.

Materials and methods

Ethics statement

The study used samples from a previously reported parent study [27]. Ethical approval was received from the Kenya Medical Research Institute Science and Ethics Review Unit (SERU-3530). Informed consent for study participation and sample storage was obtained from each child's parent/guardian.

Study population

Recruitment of study participants is reported elsewhere [27]. In summary, HIV-infected children aged 1–11 years were recruited into a cross-sectional study between October 2010 and May 2012 during care or first visit to the Kilifi County Hospital, in Coastal Kenya, where HIV-1 clade A is predominant. At the time of recruitment, the WHO's treatment guidelines recommended: all those less than 24 months: combination ART (cART); 25–59 months: cART if CD4⁺ T-cell percent less than 25% and/or if in WHO clinical stage 3 or 4; greater than 60 months: cART if their CD4⁺ T-cell percent less than 20% and/or if in WHO clinical stage 3 or 4 [28]. Of the 121 children invited for study participation, guardians/parents of 50 children self-reported that the child had not initiated ART, and these children were included in this study.

Determination of HIV-specific antibody neutralization breadth

Antibody neutralization was determined against a globally representative panel of 12 viruses belonging to subtypes A ($n = 1$), B ($n = 2$), C ($n = 3$), G ($n = 1$) and circulating recombinant forms (CRFs) ($n = 5$) [15,29]. Neutralization was measured as previously described [30–33] by a reduction in luciferase gene expression after single-round infection of TZM-bl cells with Env-pseudotyped viruses. Antibody potency was calculated as the plasma dilution needed to neutralize 50% viral infectivity, and breadth as the ability to neutralize more than 50% of this multisubtype panel.

Determination of HIV-specific antibody subclass levels

Multiplex assay

A previously described multiplex assay was adapted [34], whereby microsphere beads were coupled to HIV

antigens clade A Q461.D1 gp120, clade A BG505 SOSIP, clade A 92RW020 gp140, clade A 94UG103 gp120, clade B JRFL gp140, clade B MN gp120, clade C TV-1 gp140 and clade C IAVIC22 gp120, and two control antigens HA (A/California/07/2009), HA (A/Victoria/3/75) and inactivated Tetanus toxoid. Coupled beads were incubated with diluted plasma overnight at 4 °C and the levels of total IgG and IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ and IgA₂ detected by PE-conjugated detection agents (Southern Biotech, Birmingham, Alabama, USA) using an IQue Screener Plus (IntelliCyt).

ELISA

In brief, 50 µg of the recombinant BG505 clade A gp120 (donated by Elise Landais) were used to coat plates prior to incubation with diluted test plasma. Subclass-specific antihuman immunoglobulin conjugated to alkaline phosphatase (mouse anti-IgG, anti-IgG₁, anti-IgG₂, anti-IgG₃, anti-IgG₄ or goat anti-IgA) from Southern Biotech, USA were used for antibody subclass detection. Relative arbitrary antibody units were calculated by interpolating OD readings to standard curves prepared using pooled hyper-reactive HIV-positive plasma.

Determination of HIV-specific Fc-mediated antibody functions

Antibody-dependent phagocytosis

Fluorescent neutravidin yellow-green beads (Invitrogen, Waltham, Massachusetts, USA) were coated with AVI-tag biotinylated clade A gp120 (donated by Devin Sok and Joseph Jardine). The ability of patient plasma samples to generate antigen-specific immune-complexes that a) drive their uptake by a monocytic cell line (THP-1; ATCC TIB-202), to establish antibody-dependent cellular phagocytosis (ADCP), b) drive their uptake by neutrophils enriched from healthy donor's whole blood, to establish antibody-dependent neutrophil phagocytosis (ADNP), measured by flow cytometry [21,35,36]. Neutrophils were defined as CD3⁻CD14⁻CD66b⁺ cells (antihuman CD3 AF700 and CD14 APC-Cy7 (BD Biosciences, San Jose, California, USA) and antihuman CD66b Pacific Blue (BioLegend, San Diego, California, USA)], whereas THP-1 cells were left untreated. The phagocytic activity was presented as a score calculated as the [(% cells that have taken up antigen-coupled beads) × (MFI (mean fluorescent intensity) of cells that have taken up antigen-coupled beads)]/10000.

Antibody-dependent complement deposition

Fluorescent neutravidin red beads (Invitrogen) were coupled with AVI-tag biotinylated clade A gp120 and then incubated with diluted patient plasma, prior to adding low-tox guinea pig complement (Cedarlane, Burlington, North Carolina, USA). Antibody activation of the complement resulted in release of C3, which was measured using antihuman C3 FITC goat IgG (BD Biosciences) by flow cytometry.

Antibody-dependent natural killer cell degranulation

In brief, plates were coated with AVI-tag gp120, blocked, and patient plasma added before incubating for 2 h at 37 °C. NK cells isolated from a healthy donor's whole blood were added simultaneously with anti-CD107a PE-Cy5 (BD Biosciences), Brefeldin A (Sigma) and Golgi Stop (BD Biosciences) and incubated for 5 h at 37 °C as previously reported [37]. NK cells were then stained with anti-CD56 PE-Cy7, anti-CD16 allophycocyanin (APC)-Cy7 and anti-CD3 Alexa Fluoro 700 (BD Biosciences), fixed (FIX&PERM cell fixation and permeabilization kit, Thermo Fisher Scientific, Waltham, Massachusetts, USA), and stained intracellularly with anti-IFNγ-APC and anti-MIP-1β-PE (BD Biosciences). Surface expression of CD107a and intracellular production of IFNγ and MIP1β by NK cells (CD16⁺/56⁺CD3⁻) were then analysed by flow cytometry. For each Fc-assay, a negative control (human purified IgG, Sigma) was included. Mean of signal in the negative controls wells was subtracted as background signal. The gating strategy for the Fc-mediated functions are illustrated in Supplementary Fig. 1, <http://links.lww.com/QAD/C201>.

Fc-mediated polyfunctionality

Polyfunctionality is represented as the summed *z* scores for each child's Fc-mediated function. *z* scores were determined by subtracting the mean function of all children from an individual child's value and dividing this by the standard deviation.

Analysis

Statistical analyses were performed in Graphpad Prism version 8.4.1 (GraphPad, Software, San Diego, California, USA). Mann-Whitney nonparametric tests were used to compare groups and associations determined by Spearman test. *P* less than 0.05 considered significant.

Results

Study population clinical characteristics

Children were categorized by age, as per the ART initiation WHO guidelines at the time of study [28] (Table 1). Five children had age data missing from the records, four were less than 24 months of age, 17 were between 25 and 59 months, and 24 were above 59 months of age. Forty-six percent (23 of 50) of the children were female (Table 1). Viral load data was available for 44 of 50 with a medium HIV RNA copies/ml of 36 644 [IQR, 1815–98565], median CD4⁺ cell counts/µl blood was 912 [IQR, 608–1422], median percentage CD4⁺ was 20.8 [IQR, 13.0–29.0], lymphocyte counts 4.0 [3.6–5.5] × 10³ cells/µl, whereas the median haemoglobin levels was 10.0 [10–11] mg/dl for all the children.

HIV-specific antibody neutralization activity

Neutralization breadth was determined for 44 children against a globally representative panel of 12 viruses

Table 1. Clinical characteristics of the study population at the time of sampling.

Clinical parameters		N or median [25th–75th percentile]
Age (years)	Missing	5
	<24 months	4
	25–59 months	17
	60 months	24
Gender	Female	23
	Male	27
% CD4 ⁺	<24 months	22.4 [14.6–30.2]
	25–59 months	20.7 [15.4–30.9]
	60 months	20.8 [9.3–25.9]
	All children	20.8 [13.0–28.8]
CD4 ⁺ cell count (cells/μl)	<24 months	1979 [1201–2739]
	25–59 months	1034 [759–1580]
	60 months	715 [567–1052]
	All children	912 [608–1422]
Viral load (copies/ml)	<24 months	1314.5 [913.5–272 752]
	25–59 months	37075 [2687–123 335]
	60 months	36749 [7632–92 559]
	All children	36 644 [1815–98 565]
Lymphocyte count (10 ³ /μl)	<24 months	8.1 [6.4–12.5]
	25–59 months	5.0 [4.0–5.9]
	60 months	3.8 [3.4–4.3]
	All children	4.0 [3.6–5.5]
Hb conc. (mg/dl)	<24 months	10.0 [8–12]
	25–59 months	10.0 [9–11]
	60 months	10.5 [10–11]
	All children	10.0 [10–11]

Baseline characteristics for the children at enrolment into study. Children were divided into age brackets as per the WHO ART initiation guidelines at the time of study. Five children had age missing from the data records and age is indicated as missing. Lymphocyte counts are represented as counts per 10³ cells per μl of blood. All children; total number of children included in the study, N, total number of children; Hb, haemoglobin.

(6 children were excluded as EDTA plasma was not available, and heparin plasma results in high background in this assay) (Fig. 1a). Of the 44 plasma samples tested,

five showed activity against murine leukaemia virus (MuLV) envelope pseudotyped-viruses, a negative control, suggesting these plasmas contained antiretroviral drugs, despite self-reporting. These children were, therefore, excluded from all further analysis.

Virus neutralization ranged from 0 to 100% breadth against this panel, with potency highest against the tier 1 virus 398F1, and moderate titres against the rest, which are tier 2 viruses, more typical of circulating strains (Fig. 1a). Fifty-four percent of the children (21 of 39) neutralized more than half of the viruses tested and were defined as broad neutralizers in this study, including three children who neutralized all the viruses in this panel. Neutralization breadth was significantly higher in the older children, plateauing at about 4 years after infection (Fig. 1b) similar to studies of neutralization breadth in adults [32,33]. Plasma neutralization breadth and geometric mean titre were linearly associated (Spearman’s rho = 0.98, P < 0.0001) (Supplementary Fig. 2a, <http://links.lww.com/QAD/C202>), and therefore, neutralization breadth was used in all downstream association analyses.

HIV-specific antibody levels and subtypes

We next assessed HIV-specific antibody levels and isotype-specific binding to several HIV antigens. All children had IgG responses to the clade A BG505 gp120, as measured by ELISA. A large proportion of these were IgG₁ with antibody levels to the other IgG subclasses or IgA being lower (Supplementary Fig. 3a, <http://links.lww.com/QAD/C203>).





Fig. 1. HIV-specific antibody neutralization function. (a) Antibody neutralization was determined against 12 globally representative viruses using the TZM-bl neutralization assay. Neutralization titre is represented as the reciprocal of the plasma dilution required to inhibit 50% virus infection (ID₅₀). Data shown as a heat map with titres greater than 1000 in red, 100–999 in orange, 41–99 in yellow and less than 40 in white. Titres of 1 : 40 or less indicate no neutralization. Neutralization breadth per sample; percentage of viruses neutralized. Potency; plasma dilution needed to achieve 50% viral infectivity and the geometric mean determined. (b) Neutralization breadth by age. Mann-Whitney test used and median and range indicated. P less than 0.05 considered significant.




Fig. 2. Comparison of HIV-specific antibody levels in children with and without antibody neutralizing breadth. Antigen-specific IgG₁, IgG₂, IgG₃, IgG₄, IgA₁ and IgA₂ antibodies were quantified using an antigen-specific isotype multiplex assay. x-axis, antigens tested, y-axis log₁₀ transformed mean fluorescence intensity (MFI). Blue open circles indicate children with less than 50% neutralization breadth; red open circles indicate children with greater than 50% neutralization breadth. The median of antibody levels against each antigen is presented. Nonparametric Mann–Whitney test with *P* less than 0.05 being significant used for comparison. Each sample was analysed in technical duplicates. H1, A/California/07/2009; H3, A/Victoria/3/75; TT; inactivated Tetanus toxoid.

A similar pattern in antibody classes and isotype levels was observed using a multiplex microsphere bead assay incorporating a range of HIV antigens (Fig. 2). Antibody cross-reactivity to envelopes from clades B and C were observed and for some of the antigens, binding was at similar levels to the clade A antigen responses. Similar to the ELISA data, the predominant antibody subclass was IgG₁. For IgG₁, IgG₂ and IgG₄, binding levels to several antigens were higher in children who developed neutralization breadth. This was HIV-specific as anti-tetanus toxoid and anti-HA influenza antibodies (Fig. 2) and total IgG were similar in both groups (Supplementary Fig. 3b, <http://links.lww.com/QAD/C203>).

HIV-specific Fc-mediated antibody functions and polyfunctionality in children

Fc-mediated functions varied across the participants and by function. Complement deposition was detected in only 16% (8 of 50) of children, as expected from the low IgM titres and IgG₃ titres observed. A large proportion of the children's plasma, initiated phagocytosis either by a monocyte cell line THP-1 (ADCP) (100% of the children), or by neutrophil uptake (ADNP) (82% of the children) (Fig. 3a) with these two assays correlating (Spearman $\rho = 0.58$, $P < 0.0001$) confirming similar mechanisms (Supplementary Fig. 4a, <http://links.lww.com/QAD/C204>) [38]. The expression of CD107a (a

marker expressed upon natural killer cell degranulation) and IFN γ and MIP-1 β , two intracellular cytokines produced upon activation, were measured as proxies of antibody-dependent natural killer (ADNK) cell function. These were variable across samples, with ADNK_{CD107a}, ADNK_{IFN γ} , ADNK_{MIP-1 β} detected in 98, 58, and 60% of children, respectively. CD107a expression and IFN γ and MIP-1 β production were directly correlated as previously observed [21,39] (Supplementary Fig. 4b–d, <http://links.lww.com/QAD/C204>). Therefore, either of these markers could be used independently as a marker for natural killer cell function.

Z scores for each Fc function were used to compare the distribution of functions between neutralizers and nonneutralizers. A positive *z* score was more common in children who developed neutralization breadth suggesting the possibility of common determinants for function (Fig. 3b). To establish if these independent Fc-mediated functions were coordinated, we calculated a polyfunctionality score. A summed *z* score greater than 0 represented coordinated Fc-mediated functions (Fig. 3c). Thirty-six children with a polyfunctionality score had neutralization data available. Notably, 13 of 18 of the children who generated neutralization breadth showed coordinated Fc-mediated antibody functions compared with five of 18 of the children with poor neutralization




Fig. 3. HIV-specific Fc-mediated antibody functions. The ability of diluted children plasma to drive the uptake of gp120-coated fluorescent beads by THP-1 cells [antibody-dependent cellular phagocytosis (ADCP)], by neutrophils [antibody-dependent neutrophil phagocytosis (ADNP)], promote complement deposition [antibody-dependent complement deposition (ADCD)]; or activate NK cells [antibody-dependent natural killer (NK) cell degranulation (ADNK)] reflected by surface expression of CD107a and IFN γ and MIP-1 β production was evaluated. (a) Median functional score for the tested Fc-mediated functions. Median score shown, open circles; HIV-negative controls, closed circles; HIV-positive participants. (b) z scores for each child's Fc-mediated functions. (c) Polyfunctionality score (summed z scores of each Fc-mediated function for each child). Experiments were performed in duplicates.

breadth. Our data show that the development of neutralization breadth was associated with a more coordinated Fc-mediated function.

Association of antibody titres and functions with clinical parameters

Given the range of Fc effector functions and antibody titres in this cohort, we sought to understand the association of these with clinical parameters, such as age, CD4⁺ frequency (% of total PBMCs), CD4⁺ counts and viral load. As HIV infection in this cohort was a result of vertical transmission from mother to child, the child's age reflects duration of HIV infection.

As the pattern of antibody levels was similar across the eight gp120 HIV antigens tested (Fig. 2), BG505 SOSIP responses, representative of the prevailing clade in the study region, were tested for their association with antibody function (Fig. 4). IgG antibody levels directly correlated with neutralization breadth (Spearman's $\rho = 0.3954$, $P = 0.0170$) and with ADCD, ADCP, ADNP, ADNK_{IFN γ} and ADNK_{MIP-1 β} secretion (Supplementary Table 1, <http://links.lww.com/QAD/C205>). Similarly, the coordinated Fc-mediated function represented by the polyfunctional score was associated with IgG titres (Spearman's $\rho = 0.5769$, $P = 0.0001$).




Fig. 4. Heatmap representation of HIV-specific antibody function association with clinical outcomes, antibody levels and classes/subtypes: Spearman rho is shown where P less than 0.05, white boxes represent no significant association. ADCD, antibody-dependent complement deposition; ADCP, antibody-dependent cellular phagocytosis; ADNK, antibody-dependent natural killer (NK) cell degranulation functions; ADNP, antibody-dependent neutrophil phagocytosis; NEUT BREADTH, neutralization breadth.

IgG subclasses IgG₁, IgG₂ and IgG₄ were also directly associated with antibody neutralization breadth (Supplementary Table 1, <http://links.lww.com/QAD/C205>, Spearman's $\rho = 0.5456$, $P = 0.0012$; Spearman's $\rho = 0.8114$, $P = 0.0001$; Spearman's $\rho = 0.4892$, $P = 0.0045$, respectively) but IgG₃ was not. Additionally, both IgG₁ and IgG₂ sub-classes showed strong associations with individual Fc-mediated functions, and with the overall polyfunctionality, whereas IgG₃ and IgG₄ were poorly associated. IgA antibody levels were also associated with neutralization breadth (Spearman's $\rho = 0.4621$, $P = 0.0046$) and this association was observed for both the IgA₁ and IgA₂ subclasses. Similarly, IgA antibody levels were correlated with all Fc-mediated functions tested, and a strong association with Fc-mediated polyfunctionality score was also observed (Spearman's $\rho = 0.6313$, $P = 0.0001$). Overall, higher antibody levels reflected better HIV-specific antibody functions.

As suggested in Fig. 1b, there was a direct association between age and neutralization breadth (Supplementary Table 1, <http://links.lww.com/QAD/C205>, Spearman's $\rho = 0.3766$, $P = 0.0258$). Some Fc-mediated functions, namely ADNP and ADNK, also showed an association with age, suggesting these antibody functions improved

over time. However, ADCP and ADCD were not associated with age, suggesting these Fc-mediated functions are generated early in infection and do not significantly improve over time.

Neutralization breadth was negatively associated with both CD4⁺ cell counts and percentage as in previous studies [15] (Supplementary Table 1, <http://links.lww.com/QAD/C205>, Spearman's $\rho = -0.4663$, $P = 0.0054$, Spearman's $\rho = -0.3454$, $P = 0.0490$, respectively). However, Fc-mediated functions were less strongly associated with reduced CD4⁺ cell counts and percentages. Although a consistent trend was observed, significance was only achieved for ADNP and ADNK_{MIP-1 β} expression (Spearman's $\rho = -0.4582$, $P = 0.0020$; Spearman's $\rho = -0.4120$, $P = 0.0074$) and for the polyfunctionality score (Spearman's $\rho = -0.3821$, $P = 0.0115$). HIV-specific antibody functions were, therefore, not associated with slowed clinical deterioration. There was no significant association between viremia and neutralization breadth (Spearman's $\rho = 0.1509$, $P = 0.3870$) or the different Fc-mediated antibody functions.

Taken together, these data suggest that neutralizers have greater, broader, and more functional humoral responses,

which are in some cases correlated with age and CD4⁺ cell count, but independent of viral load.

Discussion

Here, we measured HIV-specific antibody levels, neutralization breadth and Fc-mediated functions in chronically HIV-infected, ART-naïve children. Neutralization breadth developed in more than half of the children and correlated with Fc-mediated functions, suggesting shared determinants of enhanced antibody function exist. Our observations support children's ability to recognize and mount robust immune responses against HIV antigens, confirming the potential of this target population for HIV immunization strategies.

Emerging data suggests that a larger proportion of children than adults develop neutralization breadth [14,15,40]. In agreement with this, we observed that 54% of the children neutralized more than 50% of the viruses in the representative test panel. Extended viral exposure may have allowed for activation of multiple B-cell lineages, favouring the acquisition of neutralization breadth. Additionally, higher numbers of effector T-follicular helper cells in children [41] may provide enhanced help than in adults for B-cell differentiation.

In this cross-sectional study, viral load was not an independent predictor of neutralization breadth. It is likely that the quality of antibody function at the time of sampling was determined by earlier or accumulated events over the course of infection, such as early viremia, as has been previously demonstrated [33]. The modest association previously reported [15] further supports the existence of alternative drivers of breadth in addition to viraemia.

Antibody neutralization breadth correlated with total IgG, IgG₂ and IgA titres. Although IgG₂ responses were lower, as previously reported [42,43], a strong association with neutralization breadth was observed, similar to adults [26]. Low peripheral IgA antibody levels were observed, in agreement with expected dominance in the mucosal environment [44,45]. However, these were highly associated with neutralization. It is likely that multiple Fc-related mechanism are involved in viral control [46,47] and that a balance in subtype and class distribution is necessary for the generation of antibody neutralization breadth [47]. Further studies to understand this linkage are necessary.

Only a small proportion of children had plasma antibodies that could drive complement deposition (ADCD). The undetectable levels of IgM (data not shown) and low IgG₃ antibody levels, both good mediators of complement, may have contributed to low complement deposition. It

is possible that after years of infection, circulating HIV-specific antibodies in these children were largely switched to IgG subtype [45]. IgM, a first-line antibody may have been detected earlier in infection and not at this chronic phase [48]. However, in the few children where ADCD was detectable, there was a strong association between complement deposition and total IgG and IgA as previously observed [26,49] and with IgG₁. Higher IgG levels may have resulted in more IgG-antigen complex formation. Similarly, ADCD showed strong association with neutralization breadth supporting previous reports [26]. A potential mechanism for this association is the binding of C3 to complement-receptor-2 on follicular dendritic cells, which may improve antigen presentation in the germinal centres leading to higher affinity maturation and improved antibody breadth [50,51].

Unlike ADCD, the other Fc-mediated functions were more common. All the children in this cohort mediated ADCP, and the phagocytic score was high for most children as has been observed in adults over the course of HIV infection [26]. In RV144 vaccinees, depletion of IgG₃ antibodies led to a significant loss of ADCP, although other subclasses were shown to be involved [52]. In our chronic infection cohort, few children had detectable levels of IgG₃. Decreasing levels of IgG₃ with disease progression have been previously reported [45,53,54] and may reflect downstream antibody switching. It is likely that the ADCP antibody function we observed was driven by highly functional IgG₁ antibodies [55,56]. We further assayed phagocytosis via neutrophils (ADNP). Neutrophils are common and active in all sites of HIV infection. Phagocytosis by neutrophils has been reported to peak much faster than primary NK cell or monocyte-mediated responses suggesting its role in early viral control [57]. The induction of phagocytosis via distinct innate Fc effector cell types would be beneficial in mounting efficient viral clearance mechanisms.

We then measured multiple effector functions of activated NK cells including degranulation and the release of IFN γ and MIP-1 β cytokines as proxies of antibody-dependent cell death. Previous comparisons have shown association between ADCC to CD107a degranulation [58] and in our study, there was positive correlation between CD107a, IFN γ and MIP-1 β as previously observed [21,39] suggesting that either of these markers could be used as a proxy for ADCC. IgG₁ mediates antiviral functions by binding to FcR, mediating ADCC of infected cells [59] and may have been critical in mediating the effector functions.

Previous studies suggest that multiple Fc-mediated functions provide superior viral clearance mechanisms by recruiting multiple players of innate immunity [21,26,37]. Here, 23 out of 50 (46%) children generated coordinated Fc-mediated functions. Importantly, a larger

proportion of children who showed coordinated Fc-mediated effector functions also generated neutralization breadth, suggesting that antibodies function synergistically, consistent with emerging data of joint regulation of Fc-mediated and Fab-mediated antibody functions [26,60,61]. The identification of signatures for germinal centre activities that link these processes may be exploited in vaccine design to drive desired multifunctional antibody responses.

One limitation of the study is that IgG was not purified prior to performing the assays, which would have enabled a more realistic comparison of antibody 'quality'. The cross-sectional study design also limited the association with earlier events, such as viral set point and changes over time or with clinical outcome.

Our findings show that children mount potent antibody responses to HIV antigens and that a large proportion develop neutralization breadth and Fc-mediated antibody functions. HIV vaccination strategies targeting children may, therefore, prove more likely to yield desired responses. The use of a coordinated multifunctional systems approach in key populations, such as paediatric donors, thus provides a comprehensive characterization of desirable antibody functions.

Acknowledgements

We thank the study participants, the field workers, hospital staff for their dedicated care and keeping hospital records, Dr Simone Richardson for a critical review of the manuscript and the International AIDS Vaccine Initiative (IAVI) for facilitating EWN's collaboration. This manuscript is published with permission of the Director Kenya Medical Research Institute (KEMRI).

E.W.N., D.M.M., T.N., G.A. and P.L.M. contributed to the conception and design of the study, E.W.N., M.G., Y.S., T.H., D.Y. and I.O. performed the experiments, E.W.N. drafted the manuscript, D.M.M., M.G., T.N. and P.L.M. reviewed the manuscript.

E.W.N. and Y.S. are supported by the DELTAS Africa Initiative (DEL-15-003). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (107769/Z/10/Z) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.

I.O., D.M.M. and T.N. are supported by the sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust (grant # 107752/Z/15/Z) and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government. M.G., D.Y. and G.A. are supported by the Ragon Institute of MGH, MIT and Harvard. T.N., (grant number 64809), T.H. and P.L.M. (grant number 98341) are supported by the South African Department of Science and Innovation through the National Research Foundation (South African Research Chairs Initiative).

Funding: this work was supported through a collaborative grant from the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative (grant # DEL-15-006). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant # 107752/Z/15/Z] and the UK government. The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust or the UK government.

HIV antigens were kind donations from Drs Devin Sok, Joseph Jardine and Elise Landais, USA.

Conflicts of interest

There are no conflicts of interest.

References

1. Moldt B, Rakasz EG, Schultz N, Chan-Hui PY, Swiderek K, Weisgrau KL, *et al.* **Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo.** *Proc Natl Acad Sci USA* 2012; **109**:18921–18925.
2. Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, *et al.* **Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.** *J Exp Med* 2014; **211**:2061–2074.
3. Barouch DH, Whitney JB, Moldt B, Klein F, Oliveira TY, Liu J, *et al.* **Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys.** *Nature* 2013; **503**:224–228.
4. Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather DN, Marcovecchio PM, *et al.* **Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.** *J Exp Med* 2013; **210**:1235–1249.

5. Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, *et al.* **HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.** *Nature* 2012; **492**:118–122.
6. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP Jr, Buckley N, *et al.* **Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.** *Nature* 2015; **522**:487–491.
7. Sather DN, Armann J, Ching LK, Mavrantonis A, Sellhorn G, Caldwell Z, *et al.* **Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.** *J Virol* 2009; **83**:757–769.
8. Stamatatos L. **HIV vaccine design: the neutralizing antibody conundrum.** *Curr Opin Immunol* 2012; **24**:316–323.
9. Haynes BF, Montefiori DC. **Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates.** *Exp Rev Vaccines* 2006; **5**:579–595.
10. Goulder PJ, Lewin SR, Leitman EM. **Paediatric HIV infection: the potential for cure.** *Nat Rev Immunol* 2016; **16**:259–271.
11. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, *et al.* **Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.** *J Infect Dis* 2008; **197**:563–571.
12. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, *et al.* **Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA.** *Nature* 2004; **432**:769–775.
13. Simonich CA, Williams KL, Verkerke HP, Williams JA, Nduati R, Lee KK, *et al.* **HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant.** *Cell* 2016; **166**:77–87.
14. Goo L, Chohan V, Nduati R, Overbaugh J. **Early development of broadly neutralizing antibodies in HIV-1-infected infants.** *Nat Med* 2014; **20**:655–658.
15. Muenchhoff M, Adland E, Karimanzira O, Crowther C, Pace M, Csala A, *et al.* **Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection.** *Sci Translat Med* 2016; **8**:358ra125.
16. Bournazos S, DiLillo DJ, Ravetch JV. **The role of Fc-FcγR interactions in IgG-mediated microbial neutralization.** *J Exp Med* 2015; **212**:1361–1369.
17. Bournazos S, Ravetch JV. **FcγR pathways during active and passive immunization.** *Immunol Rev* 2015; **268**:88–103.
18. Nimmerjahn F, Ravetch JV. **FcγR receptors as regulators of immune responses.** *Nat Rev Immunol* 2008; **8**:34–47.
19. Ackerman ME, Dugast AS, Alter G. **Emerging concepts on the role of innate immunity in the prevention and control of HIV infection.** *Annu Rev Med* 2012; **63**:113–130.
20. Su B, Dispinseri S, Iannone V, Zhang T, Wu H, Carapito R, *et al.* **Update on Fc-mediated functions against HIV-1 beyond neutralization.** *Front Immunol* 2019; **10**:2968.
21. Ackerman ME, Mikhailova A, Brown EP, Dowell KG, Walker BD, Bailey-Kellogg C, *et al.* **Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control.** *PLoS Pathogens* 2016; **12**:e1005315.
22. Corey L, Gilbert PB, Tomaras GD, Haynes BF, Pantaleo G, Fauci AS. **Immune correlates of vaccine protection against HIV-1 acquisition.** *Sci Translat Med* 2015; **7**:rv317.
23. Bruel T, Guivel-Benhassine F, Amraoui S, Malbec M, Richard L, Bourdic K, *et al.* **Elimination of HIV-1-infected cells by broadly neutralizing antibodies.** *Nat Commun* 2016; **7**:10844.
24. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L, *et al.* **Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice.** *Cell* 2014; **158**:989–999.
25. Hessel AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, *et al.* **Fc receptor but not complement binding is important in antibody protection against HIV.** *Nature* 2007; **449**:101–104.
26. Richardson SI, Chung AW, Natarajan H, Mabvukure B, Mkhize NN, Garrett N, *et al.* **HIV-specific Fc effector function early in infection predicts the development of broadly neutralizing antibodies.** *PLoS Pathog* 2018; **14**:e1006987.
27. Muema DM, Macharia GN, Hassan AS, Mwangi SM, Fegan GW, Berkley JA, *et al.* **Control of viremia enables acquisition of resting memory B cells with age and normalization of activated B cell phenotypes in HIV-infected children.** *J Immunol* 2015; **195**:1082–1091.
28. WHO. **Antiretroviral therapy for HIV infection in infants and children. Recommendations for a public health approach 2010 revision.** 2010.
29. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. **HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.** *Aids* 2007; **21**:693–702.
30. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, *et al.* **Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.** *Antimicrob Agents Chemother* 2002; **46**:1896–1905.
31. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, *et al.* **Antibody neutralization and escape by HIV-1.** *Nature* 2003; **422**:307–312.
32. Landais E, Huang X, Havenar-Daughton C, Murrell B, Price MA, Wickramasinghe L, *et al.* **Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort.** *PLoS Pathog* 2016; **12**:e1005369.
33. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, Tumba NL, *et al.* **The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection.** *J Virol* 2011; **85**:4828–4840.
34. Brown EP, Licht AF, Dugast AS, Choi I, Bailey-Kellogg C, Alter G, *et al.* **High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples.** *J Immunol Methods* 2012; **386**:117–123.
35. McAndrew EG, Dugast AS, Licht AF, Eusebio JR, Alter G, Ackerman ME. **Determining the phagocytic activity of clinical antibody samples.** *J Vis Exp* 2011; **57**:e3588.
36. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, *et al.* **A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples.** *J Immunol Methods* 2011; **366**:8–19.
37. Chung AW, Ghebremichael M, Robinson H, Brown E, Choi I, Lane S, *et al.* **Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines.** *Sci Translat Med* 2014; **6**:228–238.
38. Golay J, Valgardsdottir R, Musaraj G, Giupponi D, Spinelli O, Introna M. **Human neutrophils express low levels of FcγRIIIA, which plays a role in PMN activation.** *Blood* 2019; **133**:1395–1405.
39. Alter G, Malenfant JM, Delabre RM, Burgett NC, Yu XG, Lichterfeld M, *et al.* **Increased natural killer cell activity in viremic HIV-1 infection.** *J Immunol* 2004; **173**:5305–5311.
40. Moore PL. **The neutralizing antibody response to the HIV-1 Env protein.** *Curr HIV Res* 2018; **16**:21–28.
41. Roeder J, Maehara T, Ngoepe A, Ramsuran D, Muenchhoff M, Adland E, *et al.* **High-frequency, functional HIV-specific T-follicular helper and regulatory cells are present within germinal centers in children but not adults.** *Front Immunol* 2018; **9**:1975.
42. Klasse J, Blomberg J. **Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG.** *J Infect Dis* 1987; **156**:1026–1030.
43. Khalife J, Guy B, Capron M, Kieny MP, Ameisen JC, Montagnier L, *et al.* **Isotypic restriction of the antibody response to human immunodeficiency virus.** *AIDS Res Hum Retrovirus* 1988; **4**:3–9.
44. Rowland-Jones S. **Dimers are a girl's best friend.** *Nat Med* 1997; **3**:1199–1200.
45. Tomaras GD, Haynes BF. **HIV-1-specific antibody responses during acute and chronic HIV-1 infection.** *Curr Opin HIV AIDS* 2009; **4**:373–379.
46. Tjiam MC, Taylor JP, Morshidi MA, Sariputra L, Burrows S, Martin JN, *et al.* **Viremic HIV controllers exhibit high plasmacytoid dendritic cell-reactive opsonophagocytic IgG antibody responses against HIV-1 p24 associated with greater antibody isotype diversification.** *J Immunol* 2015; **194**:5320–5328.
47. French MA, Abdulai LN, Fernandez S. **Isotype diversification of IgG antibodies to HIV Gag proteins as a therapeutic vaccination strategy for HIV infection.** *Vaccines (Basel)* 2013; **1**:328–342.
48. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, *et al.* **Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma antigenp41 antibodies with ineffective control of initial viremia.** *J Virol* 2008; **82**:12449–12463.

49. E-B Rossheim A, Cunningham TD, Hair PS, Shah T, Cunnion KN, Troy SB. **Effects of well controlled HIV infection on complement activation and function.** *J Acquir Immune Defic Syndr* 2016; **73**:20–26.
50. Carroll MC, Isenman DE. **Regulation of humoral immunity by complement.** *Immunity* 2012; **37**:199–207.
51. Fang Y, Xu C, Fu YX, Holers VM, Molina H. **Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response.** *J Immunol* 1998; **160**:5273–5279.
52. Chung AW, Crispin M, Pritchard L, Robinson H, Gorny MK, Yu X, *et al.* **Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function.** *AIDS* 2014; **28**:2523–2530.
53. Ljunggren K, Broliden PA, Morfeldt-Manson L, Jondal M, Wahren B. **IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages.** *Clin Exp Immunol* 1988; **73**:343–347.
54. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, *et al.* **Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.** *J Virol* 2008; **82**:11651–11668.
55. Hristodorov D, Fischer R, Linden L. **With or without sugar? (A)glycosylation of therapeutic antibodies.** *Mol Biotechnol* 2013; **54**:1056–1068.
56. Chung AW, Kumar MP, Arnold KB, Yu WH, Schoen MK, Dunphy LJ, *et al.* **Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology.** *Cell* 2015; **163**:988–998.
57. Worley MJ, Fei K, Lopez-Denman AJ, Kelleher AD, Kent SJ, Chung AW. **Neutrophils mediate HIV-specific antibody-dependent phagocytosis and ADCC.** *J Immunol Methods* 2018; **457**:41–52.
58. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. **Rapid degranulation of NK cells following activation by HIV-specific antibodies.** *J Immunol* 2009; **182**:1202–1210.
59. Perez LG, Costa MR, Todd CA, Haynes BF, Montefiori DC. **Utilization of immunoglobulin G Fc receptors by human immunodeficiency virus type 1: a specific role for antibodies against the membrane-proximal external region of gp41.** *J Virol* 2009; **83**:7397–7410.
60. Kinoshita K, Honjo T. **Linking class-switch recombination with somatic hypermutation.** *Nat Rev Mol Cell Biol* 2001; **2**:493–503.
61. Janda A, Bowen A, Greenspan NS, Casadevall A. **Ig constant region effects on variable region structure and function.** *Front Microbiol* 2016; **7**:22.